We maintain BUY but revised our FV to RM2.10/share (from RM2.19) as we change the valuation method from PB to PE given the continuity in earnings. We raised our FY18/19/20 projections by 34%/44%/44% with the assumption of lower operating costs and stronger overseas earnings. Our new FV is based on an FY19F PE of 13.0x (previously: PBV of 0.5x).
TCM’s YTD core net profit of RM69mil exceeded expectations, meeting 103% of our FY projection and 125% of consensus.
TCM’s 3QFY18 benefited from the tax holiday and popularity of the Serena MPV. Core net profit of RM35mil (up 73% QoQ, 121% YoY) was anchored to the spike in Nissan sales in Malaysia and a turnaround for its lossmaking operations in Vietnam. Recall that Vietnam was previously the last of the group’s Indochina operations to be in the red due to poor utilization rates.
TCM’s YTD core net profit of RM69mil was a massive swing from the RM93mil loss in the previous corresponding period, as it stayed in the black for three straight quarters following two years in the red.
This reflected its success from pursuing margins rather than volume: YTD sales in Malaysia were flat YoY but domestic revenue improved 13% and EBITDA jumped 136% as EBITDA margin rose 4ppts to 7%.
Inventory/inventory turnover days (RM909mil/221 days) and net debt/gearing (RM805mil/0.3x) both fell below the RM1bil threshold to see their best level in over two years. This led to a better operating cash flow and lower net finance costs for the YTD period, consequently playing a small part in taking TCM’s PBT margin into positive territory.
We project a FY18/FY19 sales growth of 2%/5% premised on an average of 2.3K/month sold in the final quarter of FY18 and possible additions next year.
The Serena MPV accounts for a third of Nissan monthly sales and has only been around for six months. As the momentum from this slows, we believe new launches should come to target Nissan’s other segments: passenger cars and SUVs. TCM should adopt a similar strategy and prioritize on margins rather than competing for volume.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....